{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:42Z","timestamp":1786980102699,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007760","name":"College of Medicine Office of Research, Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007760","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome is a rare condition characterized by clinical features of all three dermatologic conditions. The management of PASH syndrome is difficult, with no consensus on treatment guidelines. Since PASH syndrome can increase morbidity and adversely impact quality of life, better characterization of effective therapies is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted to identify all patients with pyoderma gangrenosum (PG) treated at The Ohio State University Wexner Medical Center between 2015 and 2021. PG diagnosis was confirmed via PARACELSUS score. Subsequent chart review identified eight patients with concomitant hidradenitis suppurativa (HS) and acne who were clinically diagnosed with PASH syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight patients were clinically diagnosed with PASH syndrome based on their clinical presentation at our institution. Seven patients had failed some type of medical therapy prior to presentation, including topical corticosteroids, oral corticosteroids, oral antibiotics, and biologics. One patient had also tried surgical drainage at an outside institution. Six patients were effectively treated with biologics, usually in combination with other therapies. One patient experienced improvement of her skin lesions after diagnosis and treatment of her underlying hematologic malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medical management with biologics in combination with corticosteroids and\/or antibiotics was effective in the management of most patients. Diagnosis and treatment of an underlying condition should be prioritized in refractory cases. If workup is negative, surgical management may be considered. Further investigation with a greater number of patients is required to develop management guidelines for PASH syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00403-024-03125-7","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:01:41Z","timestamp":1718431301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management"],"prefix":"10.1007","volume":"316","author":[{"given":"Allison","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Savu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"3","key":"3125_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","volume":"66","author":"M Braun-Falco","year":"2012","unstructured":"Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T (2012) Pyoderma Gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol Mar 66(3):409\u2013415. https:\/\/doi.org\/10.1016\/j.jaad.2010.12.025","journal-title":"J Am Acad Dermatol Mar"},{"issue":"4","key":"3125_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","volume":"18","author":"M Cugno","year":"2017","unstructured":"Cugno M, Borghi A, Marzano AV, PAPA, PASH, Syndromes PAPASH (2017) Pathophysiology, presentation and treatment. Am J Clin Dermatol Aug 18(4):555\u2013562. https:\/\/doi.org\/10.1007\/s40257-017-0265-1","journal-title":"Am J Clin Dermatol Aug"},{"issue":"11","key":"3125_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/jdv.14464","volume":"31","author":"J Gasparic","year":"2017","unstructured":"Gasparic J, Theut Riis P, Jemec GB (2017) Recognizing syndromic hidradenitis suppurativa: a review of the literature. J Eur Acad Dermatol Venereol Nov 31(11):1809\u20131816. https:\/\/doi.org\/10.1111\/jdv.14464","journal-title":"J Eur Acad Dermatol Venereol Nov"},{"issue":"5","key":"3125_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000509873","volume":"237","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2021) Phenotypes and pathophysiology of Syndromic Hidradenitis Suppurativa: different faces of the same disease? A systematic review. Dermatology 237(5):673\u2013697. https:\/\/doi.org\/10.1159\/000509873","journal-title":"Dermatology"},{"issue":"2","key":"3125_CR5","first-page":"173","volume":"26","author":"V Saint-Georges","year":"2018","unstructured":"Saint-Georges V, Peternel S, Ka\u0161telan M, Brajac I (2018) Tumor necrosis factor antagonists in the treatment of Pyoderma Gangrenosum, Acne, and suppurative hidradenitis (PASH) syndrome. Acta Dermatovenerol Croat Jun 26(2):173\u2013178","journal-title":"Acta Dermatovenerol Croat Jun"},{"issue":"8","key":"3125_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/RHU.0b013e318278b84c","volume":"18","author":"V Bruzzese","year":"2012","unstructured":"Bruzzese V (2012) Pyoderma Gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor \u03b1 therapy. J Clin Rheumatol Dec 18(8):413\u2013415. https:\/\/doi.org\/10.1097\/RHU.0b013e318278b84c","journal-title":"J Clin Rheumatol Dec"},{"issue":"11","key":"3125_CR7","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/jdv.12765","volume":"29","author":"J Staub","year":"2015","unstructured":"Staub J, Pfannschmidt N, Strohal R et al (2015) Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol Nov 29(11):2243\u20132247. https:\/\/doi.org\/10.1111\/jdv.12765","journal-title":"J Eur Acad Dermatol Venereol Nov"},{"issue":"3","key":"3125_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bjd.13002","volume":"171","author":"HH van der Zee","year":"2014","unstructured":"van der Zee HH, de Winter K, van der Woude CJ, Prens EP (2014) The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol Sep 171(3):673\u2013675. https:\/\/doi.org\/10.1111\/bjd.13002","journal-title":"Br J Dermatol Sep"},{"key":"3125_CR9","doi-asserted-by":"publisher","unstructured":"Yan A, Gallardo M, Milani-Nejad N, Kaffenberger B (2023) Successful management of extensive cribriform facial scarring secondary to PASH Syndrome with a combination of Medical and Surgical treatments. Dermatol Surg Aug 10. https:\/\/doi.org\/10.1097\/DSS.0000000000003903","DOI":"10.1097\/DSS.0000000000003903"},{"issue":"3","key":"3125_CR10","doi-asserted-by":"publisher","first-page":"e0265672","DOI":"10.1371\/journal.pone.0265672","volume":"17","author":"K Seetan","year":"2022","unstructured":"Seetan K, Eldos B, Saraireh M et al (2022) Prevalence of low vitamin D levels in patients with Hidradenitis suppurativa in Jordan: a comparative cross-sectional study. PLoS ONE 17(3):e0265672. https:\/\/doi.org\/10.1371\/journal.pone.0265672","journal-title":"PLoS ONE"},{"issue":"1","key":"3125_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/09546634.2019.1621981","volume":"32","author":"AJ Hendricks","year":"2021","unstructured":"Hendricks AJ, Hirt PA, Sekhon S et al (2021) Non-pharmacologic approaches for hidradenitis suppurativa - a systematic review. J Dermatolog Treat Feb 32(1):11\u201318. https:\/\/doi.org\/10.1080\/09546634.2019.1621981","journal-title":"J Dermatolog Treat Feb"},{"issue":"2","key":"3125_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2017.09.040","volume":"78","author":"FD Xia","year":"2018","unstructured":"Xia FD, Liu K, Lockwood S et al (2018) Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. J Am Acad Dermatol Feb 78(2):310\u2013314e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.040","journal-title":"J Am Acad Dermatol Feb"},{"issue":"1","key":"3125_CR13","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1111\/bjd.15740","volume":"178","author":"H Sonbol","year":"2018","unstructured":"Sonbol H, Duchatelet S, Miskinyte S, Bonsang B, Hovnanian A, Misery L (2018) PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity. Br J Dermatol Jan 178(1):e17\u2013e18. https:\/\/doi.org\/10.1111\/bjd.15740","journal-title":"Br J Dermatol Jan"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03125-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:32:54Z","timestamp":1725899574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03125-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3125"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03125-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kaffenberger has received grants from InflaRx, consulting fees from Eli Lilly and Novartis, and payment for expert testimony related to pyoderma gangrenosum. Ms. Yan, Mr. Gallardo, and Mr. Savu have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosures"}},{"value":"This project was approved by the Ohio State University Wexner Medical Center IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}}],"article-number":"397"}}